Newsroom | 54839 results

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 27,480 shares of the Company’s common stock to seven new employees (the “Inducement Grants”) on August 6, 2025 (the “Grant Date”). The Induc...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Reports Second Quarter 2025 Financial Results...

DUBLIN--(BUSINESS WIRE)--The "Navigating ICH GCP (Good Clinical Practice) E6 (R3): What You Need to Know Training Course" training has been added to ResearchAndMarkets.com's offering. This one-day training course is designed to provide clinical research professionals with a comprehensive understanding of the updated guidelines, ensuring compliance and enhancing the quality of clinical trials. The ICH GCP E6 (R3) guideline represents a significant evolution in the conduct of clinical trials, emp...

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Participate in the UBS Precision Medicine Frontiers Summit...

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2025. “We remain focused on exploring strategic alternatives and partnerships across our portfolio to enhance long-term shareholder value, as exemplified by our recent worldwide licensing agreement with Debiopharm for lunresertib and out-licensing of early-stage disco...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June 30, 2025, and provided recent corporate updates. “We continue to execute on our strategy, which is grounded in scientific rigor and focused on fulfilling our mission to develop next-generation prec...

QUÉBEC--(BUSINESS WIRE)--Groupe Santé Devonian Inc. (« Devonian » ou la « Société ») (TSXV: GSD; OTCQB : DVHGF), une société en phase clinique spécialisée dans le développement de solutions uniques pour les maladies inflammatoires, annonce la clôture de son placement privé sans l’entremise d’un courtier pour un produit brut total de 2 272 999,85 $ (le « Placement »). Le Placement consistait en l’émission de 15 153 332 unités de la Société (les « Unités ») au prix de 0,15 $ par Unité. Chaque Uni...

明尼阿波利斯--(BUSINESS WIRE)--(美国商业资讯)-- Edison®组织摧毁术系统及新型组织摧毁术治疗平台的研发企业HistoSonics今日宣布，由一批全球知名的私人和公共投资者组成的联盟将以管理层主导的方式收购其多数股权，投资方包括K5 Global、Bezos Expeditions、Wellington Management以及其他新老投资者。此次交易对HistoSonics的估值约为22.5亿美元，将助力公司加速Edison系统在新临床适应症及全球市场的增长。 HistoSonics将继续由总裁兼首席执行官Mike Blue及其管理团队领导。交易完成后，Blue先生还将担任董事会主席一职。 Blue先生表示：“作为一家公司，我们始终专注于速度、规模，以及为患者提供比现有方案更优选择的迫切使命。这批新合作伙伴支持那些定义品类、变革整个行业的企业。他们的支持将为我们注入动力，加速发展势头，拓展至新的临床适应症，惠及全球更多急需我们突破性疗法的患者。” HistoSonics计划在初始聚焦的肝肿瘤之外，将业务扩展至肾、胰腺和前列腺肿瘤适应症，其长期愿景是让组织摧毁...

明尼亞波里斯--(BUSINESS WIRE)--(美國商業資訊)-- Edison®組織摧毀術系統及新型組織摧毀術治療平台的研發企業HistoSonics今日宣布，由一批全球知名的私人和公共投資人組成的聯盟將以管理層主導的方式收購其多數股權，投資方包括K5 Global、Bezos Expeditions、Wellington Management以及其他新投資人和現有投資人。此次交易對HistoSonics的估值約為22.5億美元，將協助公司加快Edison系統在新臨床適應症及全球市場的成長。 HistoSonics將繼續由總裁兼執行長Mike Blue及其管理團隊領導。交易完成後，Blue先生還將擔任董事長一職。 Blue先生表示：「身為一家公司，我們始終專注於速度、規模，以及為病患提供比現有方案更優選擇的迫切使命。這批新合作夥伴支援那些定義品類、變革整個產業的企業。他們的支援將為我們注入動力，加大發展動力，擴大至新的臨床適應症，嘉惠全球更多亟需我們突破性療法的病患。」 HistoSonics計畫在初始聚焦的肝腫瘤之外，將業務擴充至腎、胰腺和攝護腺腫瘤適應症，其長期願景是讓組織摧...

QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, announces that it has closed its non-brokered private placement for aggregate gross proceeds of $2,272,999.85 (the “Offering”). The Offering consisted of the issuance of 15,153,332 units of the Corporation (the “Units”) at a price of $0.15 per Unit. Each Unit consists of one subordinate...